Literature DB >> 34728766

A type 1 regulatory T cell-based therapy.

Sarah Crunkhorn.   

Abstract

Entities:  

Year:  2021        PMID: 34728766     DOI: 10.1038/d41573-021-00183-8

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.

Authors:  Pauline P Chen; Alma-Martina Cepika; Rajni Agarwal-Hashmi; Gopin Saini; Molly J Uyeda; David M Louis; Brandon Cieniewicz; Mansi Narula; Laura C Amaya Hernandez; Nicholas Harre; Liwen Xu; Benjamin Craig Thomas; Xuhuai Ji; Parveen Shiraz; Keri M Tate; Dana Margittai; Neehar Bhatia; Everett Meyer; Alice Bertaina; Mark M Davis; Rosa Bacchetta; Maria Grazia Roncarolo
Journal:  Sci Transl Med       Date:  2021-10-27       Impact factor: 19.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.